Drug product consultations

Effective consultation is essential to allow Health Canada to fulfill its legislative mandate, deliver programs, and launch new initiatives. Canadians are provided an opportunity to be involved in decision-making processes regarding Health Canada's priorities, policies and programs.

• Consultation: Proposed application of the definition of Canadian Reference Product (CRP) [2023-03-27]
• Consultation: Registration of Clinical Trials and Public Disclosure of Results: Draft Guidance and Public Search Portal [2023-03-23]
• Consultation: Exceptions to the Prescription Drug List [2022-07-28]
• Comment on the draft revised Guidance document: Switching a medicinal ingredient from prescription to non-prescription status [2022-04-21]
• Consultation Notice: Health Canada Requests Feedback on Potential Impacts and Uses if Company Names were added to the Generic Submissions Under Review List [2019-01-17]
• Consultation on fee proposal for drugs and medical devices [2017-10-11]
• Notice of Consultation - Prescription Drug List (PDL): Veterinary and Human Antimicrobials
• Consultation on the Prescription Drug List: Hydroquinone [2017-02-01]
• Consultation on the Prescription Drug List: Naloxone [2017-01-24]
• Consultation on the Draft Guidance Document - Cancellation of a Drug Identification Number (DIN) and Notification of the Discontinuation of Sales [2016-06-30]
• Consultation on the Draft guidance document: Disclosure of Confidential Business Information under Paragraph 21.1(3)(c) of the Food and Drugs Act [2016-03-10]
• Consultation on Health Product Transparency Initiatives [2015-01-25]
• Consultation - Prescription Drug List (PDL): Naloxone [2016-01-14]
• Consultation - Release of Draft (Step 2) ICH Guidance Document E18: Genomic Sampling and Management of Genomic Data [2016-01-08]
• Consultation - Prescription Drug List (PDL): Fluticasone propionate [2015-11-27]
• Consultation on the Prescription Drug List: Hyoscine butylbromide [2015-10-16]
• Consultation - Prescription Drug List (PDL): Ibuprofen [2015-10-02]
• Consultation - Prescription Drug List (PDL): Esomeprazole [2015-10-02]
• Consultation - Release of Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance: M4E(R2): Enhancing the Format and Structure of Benefit-Risk Information in ICH [2015-08-19]
• Consultation - Prescription Drug List (PDL): Polymyxin B [2015-06-19]
• Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on International Conference on Harmonisation Guidelines for Registration of Pharmaceuticals for Human Use [2015-04-10]
• Protecting Canadians from Unsafe Drugs Act Transparency Needs-based Assessment [2015-03-25]
• Consultation on the Amendments to the Food and Drugs Act: Guide to New Authorities (power to require & disclose information, power to order a label change and power to order a recall) [2015-03-25]
• Consultation - Release of Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use Guidance: M8 - Electronic Common Technical Document: Implementation Guide [2015-03-16]